← Product Code [GCJ](/productcode/GCJ) · K974592 # INTERCEPTRE LAPAROSCOPIC INSTRUMENTS (K974592) _Smith & Nephew, Inc. · GCJ · Jan 12, 1998 · Gastroenterology, Urology · SESE_ **Canonical URL:** https://fda.innolitics.com/device/K974592 ## Device Facts - **Applicant:** Smith & Nephew, Inc. - **Product Code:** [GCJ](/productcode/GCJ.md) - **Decision Date:** Jan 12, 1998 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 876.1500 - **Device Class:** Class 2 - **Review Panel:** Gastroenterology, Urology - **Attributes:** Therapeutic ## Indications for Use The Interceptre™ Endoscopic Instruments are a family of graspers, dissectors, and scissors which are intended to be used to grasp, manipulate, cut, cauterize soft tissue. ## Device Story Interceptre™ Endoscopic Instruments are hand-held, reusable, non-sterile surgical tools including graspers, dissectors, and scissors. Used in endoscopic/laparoscopic procedures to grasp, manipulate, cut, and cauterize soft tissue. Operated by surgeons in clinical settings. Design features dual/single action jaw with 360-degree rotation. Constructed from stainless steel with Kynar insulation. Device functions as a mechanical surgical accessory; no electronic or software components. ## Clinical Evidence No clinical data provided; bench testing only. ## Technological Characteristics Reusable, non-sterile endoscopic instruments. Materials: stainless steel and Kynar insulation. Design: 3-component assembly, dual/single action jaw, 360-degree rotation. Manual operation; no energy source, connectivity, or software. ## Regulatory Identification An endoscope and accessories is a device used to provide access, illumination, and allow observation or manipulation of body cavities, hollow organs, and canals. The device consists of various rigid or flexible instruments that are inserted into body spaces and may include an optical system for conveying an image to the user's eye and their accessories may assist in gaining access or increase the versatility and augment the capabilities of the devices. Examples of devices that are within this generic type of device include cleaning accessories for endoscopes, photographic accessories for endoscopes, nonpowered anoscopes, binolcular attachments for endoscopes, pocket battery boxes, flexible or rigid choledochoscopes, colonoscopes, diagnostic cystoscopes, cystourethroscopes, enteroscopes, esophagogastroduodenoscopes, rigid esophagoscopes, fiberoptic illuminators for endoscopes, incandescent endoscope lamps, biliary pancreatoscopes, proctoscopes, resectoscopes, nephroscopes, sigmoidoscopes, ureteroscopes, urethroscopes, endomagnetic retrievers, cytology brushes for endoscopes, and lubricating jelly for transurethral surgical instruments. This section does not apply to endoscopes that have specialized uses in other medical specialty areas and that are covered by classification regulations in other parts of the device classification regulations. ## Special Controls *Classification* —(1)*Class II (special controls).* The device, when it is an endoscope disinfectant basin, which consists solely of a container that holds disinfectant and endoscopes and accessories; an endoscopic magnetic retriever intended for single use; sterile scissors for cystoscope intended for single use; a disposable, non-powered endoscopic grasping/cutting instrument intended for single use; a diagnostic incandescent light source; a fiberoptic photographic light source; a routine fiberoptic light source; an endoscopic sponge carrier; a xenon arc endoscope light source; an endoscope transformer; an LED light source; or a gastroenterology-urology endoscopic guidewire, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.(2) Class I for the photographic accessories for endoscope, miscellaneous bulb adapter for endoscope, binocular attachment for endoscope, eyepiece attachment for prescription lens, teaching attachment, inflation bulb, measuring device for panendoscope, photographic equipment for physiologic function monitor, special lens instrument for endoscope, smoke removal tube, rechargeable battery box, pocket battery box, bite block for endoscope, and cleaning brush for endoscope. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807of this chapter, subject to the limitations in § 876.9. In combination with the general controls of the FD&C Act, the integrated operating table-electromechanical surgical system is subject to the following special controls: 1. (1) Premarket clinical performance testing, or a combination of premarket clinical performance testing and postmarket surveillance (in accordance with special control (2)), must include the following: 1. (i) Objective performance measures (e.g., rate and number of conversions to other surgical modalities, rate of device related adverse events (including tissue injury, hematoma, and increased blood loss), and their severity, cause, and outcomes) must be reported with relevant descriptive comparator performance measures. 2. (ii) The data must demonstrate the performance of the device for providing accurate and precise control of attached surgical instruments in range of clinical conditions relevant to the device's intended use. 3. (iii) The test dataset must include data collected from a patient population representative of the intended patient population under anticipated conditions of use. 2. (2) Data obtained from postmarket surveillance must demonstrate, in consideration of the premarket data obtained in accordance with special control (1), that the device performs in accordance with special control (1), unless FDA determines, based on the totality of the premarket data, that data from postmarket surveillance is not required to demonstrate that the device performs as intended. Such postmarket surveillance must be conducted per a protocol determined appropriate by FDA to demonstrate that the device performs as intended (in consideration of the premarket data obtained in accordance with special control (1)), and must include initiation, enrollment, and reporting requirements to ensure timely periodic updates to FDA on post-market surveillance progress and outcomes. 3. (3) Animal performance testing must evaluate the extent of port site trauma due to repositioning of table during surgical procedures when utilizing robotic minimally invasive and laparoscopic approaches 4. (4) The device manufacturer must develop, and update as necessary, a device-specific use training program that ensures proper device setup/use/shutdown, accurate control of instruments to perform the intended surgical procedures, troubleshooting and handling during unexpected events or emergencies, and safe practices to mitigate use error. 5. (5) The device manufacturer may only distribute the device to facilities that implement and maintain the device-specific use training program and ensure that users of the device have completed the device-specific use training program. (6) Human factors assessment must demonstrate that the user can correctly use the device system across all intended use environments with the provided instructions and training materials, including patient access during normal operating conditions and emergency situations, and effects arising from the integrated nature of the operating table and robotic surgical arms. (7) Labeling must include: (i) A detailed summary of clinical performance testing conducted with the device, including study population, results, adverse events, and comparisons to any comparator groups identified; (ii) A statement in the labeling that the safety and effectiveness for the representative specific procedures was based on evaluation of the device as a surgical tool and did not include evaluation of outcomes related to the treatment of the patient's underlying disease or condition, unless FDA determines that it can be removed or modified based on clinical performance data submitted to FDA; (iii) Identification of compatible devices; (iv) The list of surgical procedures for which the device has been determined to be safe with clinical justification; (v) Reprocessing instructions for reusable components; (vi) A shelf life for any sterile components; (vii) A description of the device-specific use training program; (viii) A statement that the device is only for distribution to facilities that implement and maintain the device-specific use training program and ensure that users of the device have completed the device-specific use training program; and (ix) A summary of any completed postmarket surveillance data collected as required by special control (2), including updated labeling to accurately reflect outcomes observed in postmarket surveillance. (8) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use and must include: (i) Device motion accuracy and repeatability; (ii) System testing; (iii) Instrument reliability; (iv) Crosstalk; (v) Table motion control; (vi) Thermal effects on tissue; (vii) User-device interface performance; (viii) Workspace access testing; and (ix) Performance testing with compatible devices. (9) Software verification, validation, and hazard analysis must be performed. (10) Electromagnetic compatibility and electrical, thermal, and mechanical safety testing must be performed. (11) Performance data must demonstrate the sterility of all patient-contacting device components. (12) Performance data must support the shelf life of the device components provided sterile by demonstrating continued sterility and package integrity over the labeled shelf life. (13) Performance data must validate the reprocessing instructions for the reusable components of the device. (14) Performance data must demonstrate that all patient-contacting components of the device are biocompatible. (15) Performance data must demonstrate that all patient-contacting components of the device are non-pyrogenic. (16) The device manufacturer must submit a report to the FDA annually on the anniversary of initial marketing authorization for the device, until such time as FDA may terminate such reporting, which comprises the following information: (i) Cumulative summary, by year, of complaints and adverse events since date of initial marketing authorization; and (ii) Identification and rationale for changes made to the device, labeling, or device specific use training program, which did not require submission of a premarket notification during the reporting period. ## Predicate Devices - Karl Storz Take-Apart Endoscopic Instruments - Richard Wolf Laparoscopic Instruments ## Reference Devices - Smith Nephew Endoscopic Instruments ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ ## Section 5- 510k Summary of Safety and Effectiveness 16974892 This summary of 510k safety and effectiveness information is being submitted in 5.1 accordance with the requirements of SMDA 1990 and CFR 807.92 Statement Smith and Nephew, Inc. 5.2 Submitter 130 Forbes Boulevard Mansfield, Ma. 02048 、 · 5.3 Susan Finneran Company Clinical/ Regulatory Affairs Contact (508) 261-3772 Proprietary Name: Interceptre™ Laparoscopic Instruments 5.4 Common Name: Minimally Invasive Surgical Instruments: graspers, dissectors, Device Name scissors, Classification Name: Endoscopic accessories(78 GCJ) Laparoscopic accessories (85 HET) Electrosurgical accessories (79 BWA, 78 KNS) | 5.5
Predicate
Legally
Marketed
Devices | • Karl Storz Take-Apart Endoscopic Instruments
• Richard Wolf Laparoscopic Instruments | |----------------------------------------------------|-------------------------------------------------------------------------------------------| |----------------------------------------------------|-------------------------------------------------------------------------------------------| 006 {1}------------------------------------------------ The Interceptre™ Endoscopic instruments are a line of hand-held , non-sterile, ર્ડ.6 Device reusable instruments Description The Interceptre™ Endoscopic Instrumentation is intended to be used for the 5.7 management of soft tissue. The instruments are intended to be used to grasp, Intended Use dissect, and cut soft tissue. ﺷﻌﺒﻪ ﺍ The Interceptre™ Endoscopic Instrumentation is indicated for use in endoscopic 5.8 Device Indications procedures. で ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ The Interceptre™ Endoscopic Instrumentation is substantially equivalent to the રું. જેન્ડો જિલ્લાનું મુખ્યત્વે ખેતી, ખેતમજૂરી તેમ જ પશુપાલન છે. આ ગામનાં મુખ્યત્વે ખેતી, ખેતમજૂરી તેમ જ પશુપાલન મુખ્યત્વે આવેલું એક ગામનાં મુખ્યત્વે ખેતી, ખેતમજૂરી તેમ જ પશ Karl Storz Take-Apart Endoscopic Instruments and the Richard Wolf Laparoscopic Substantial Equivalence Instruments. The table below summarizes the similarities of the three product lines. The similarities between the Interceptre™ Endoscopic Instrumentation and the instruments in the other two product lines support the claim of substantial equivalence. {2}------------------------------------------------ ## TABLE OF SUBSTANTIAL EQUIVALENCE | Product Name | Interceptre MIS II Endoscopic Instruments | Karl Storz Take-Apart Endoscopic Instruments | Richard Wolf Laparoscopic Instruments | Smith Nephew Endoscopic Instruments | |-------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|-------------------------------------| | Product Labeling | non-sterile/reusable | non-sterile/reusable | non-sterile/reusable | non-sterile reusable | | Materials | Stainless steel/Kynar insulation | Stainless steel/ insulation | Stainless steel/ plastic/insulation | Stainless Steel/Kynar insulation | | Indications | Endoscopic Surgical Procedures | Endoscopic Surgical Procedures | Endoscopic Surgical Procedures | Endoscopic Surgical Procedures | | Intended Use | Management of Soft Tissue | Management of Soft Tissue | Management of Soft Tissue | Management of Soft Tissue | | Tip Styles | graspers, dissectors, scissors | graspers, dissectors, scissors | graspers, dissectors, scissors | graspers, scissors, dissectors | | Number of separate components | 3 | 3 | 3 | 1 | | Design | Dual / single action jaw design with 360 degree rotation | Dual / single action jaw design with 360 degree rotation | Dual / single action jaw design with 360 degree rotation | Dual / single action jaw design | **Applicant** Sus Penn **Date** 12/8/97 - **008** {3}------------------------------------------------ Image /page/3/Picture/1 description: The image contains the words "Public Health Service" in bold, black font. The words are stacked on top of each other, with "Public" on the top line, "Health" on the second line, and "Service" on the third line. The text appears to be extracted from a document or sign. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 JAN 1 2 1998 Ms. Susan A. Finneran Clinical/Regulatory Affairs Smith & Nephew, Incorporated Endoscopy Division 130 Forbes Boulevard Mansfield, Massachusetts 02048 Re: K974592 Trade Name: Interceptre Laparoscopic Instruments Regulatory Class: II Product Code: GCJ Dated: December 8, 1997 Received: December 9, 1997 Dear Ms. Finneran: We have reviewed your Section 510(k) notification of intent to market the devices referenced above and we have determined the devices are substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the devices, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your devices are classified (see above) into either class II (Special Controls) or class III (Premarket Approval), they may be subject to such additional controls. Existing major regulations affecting your devices can be found in the Code of Federal Regulations, Title 21, " Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirements , as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. In addition, FDA may publish further announcements concerning your devices in the Federal Register. Please note: this response to your premarket notification submissions does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. {4}------------------------------------------------ Page 2 - Ms. Finneran This letter will allow you to begin marketing your devices as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your devices to a legally marketed predicate device results in a classification for your devices and thus, permits your devices to proceed to the market. If you desire specific advice for your devices on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your devices, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html". Sincerely yours, Celia M. Witten, Ph.D., M.D. Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ 510 (k) Number (If Known): Lap aroscopic Device Name: Interceptre™ Endoscopic Instruments Indications For Use: The Interceptre™ Endoscopic Instruments are indicated for use in endoscopic/laparoscopic procedures Intended Use: The Interceptre™ Endoscopic Instruments are a family of graspers, dissectors, and scissors which are intended to be used to grasp, manipulate, cut, cauterize soft tissue. ## (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) ## Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use (Per 21 CFR 801.109) or Over-The-Counter Use __ (Division Sign-Off) Division of General Restorative Devices 510(k) Number K974592 Image /page/5/Picture/9 description: The image shows some text in a non-English language. The text appears to be repeated several times. Without translation, it is difficult to determine the meaning or context of the text. The characters are distinct and legible, suggesting it may be a printed or digital document. તું તે --- **Source:** [https://fda.innolitics.com/device/K974592](https://fda.innolitics.com/device/K974592) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com